Learn about sedative, hypnotic, and anxiolytic use disorders including benzodiazepine addiction. DSM-5 criteria, symptoms, and treatment at CommonHealth Recovery.
Understanding Sedative, Hypnotic, and Anxiolytic Substances
DSM-5 Diagnostic Criteria for Sedative, Hypnotic, or Anxiolytic Use Disorder
How Sedative, Hypnotic, and Anxiolytic Use Disorders Develop
Signs and Symptoms of Sedative, Hypnotic, or Anxiolytic Use Disorders
Health Risks and Complications
Special Populations and Considerations
Co-Occurring Mental Health Disorders
Evidence-Based Treatment for Sedative, Hypnotic, or Anxiolytic Use Disorders
Alternative Treatments for Anxiety and Sleep Disorders
Long-Term Recovery and Prognosis
Sedative, hypnotic, or anxiolytic use disorders represent a significant and often overlooked category of substance use disorders characterized by problematic use of central nervous system depressants. These disorders involve the misuse of medications prescribed for anxiety, insomnia, and other conditions—including benzodiazepines, sleep medications, and barbiturates.
At CommonHealth Recovery in Frankfort, Kentucky, we provide comprehensive evidence-based treatment for sedative, hypnotic, and anxiolytic use disorders, including medically supervised detoxification referrals, counseling, and integrated mental health care to address both the substance use and underlying conditions.
Sedatives, hypnotics, and anxiolytics are central nervous system (CNS) depressants—medications that slow brain activity, producing calming, relaxing, or sleep-inducing effects. While these medications serve important medical purposes when used as prescribed, they carry significant risks of dependence, addiction, and dangerous withdrawal.
Benzodiazepines (Anxiolytics and Hypnotics):
Benzodiazepines are among the most commonly prescribed psychoactive medications in the United States. They enhance the effect of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain, producing sedative, anxiolytic (anti-anxiety), muscle-relaxant, and anticonvulsant effects.
Common benzodiazepines include:
Non-Benzodiazepine Hypnotics (Z-Drugs):
These medications, often called “Z-drugs,” work similarly to benzodiazepines but have a different chemical structure. They’re primarily prescribed for insomnia:
Barbiturates (Sedative-Hypnotics):
Barbiturates were once widely prescribed but have largely been replaced by benzodiazepines due to their higher risk of overdose and dependence. They’re now primarily used for seizure disorders and anesthesia:
Other Sedatives and Anxiolytics:
All of these substances share the potential for tolerance, physical dependence, and withdrawal when used regularly, even as prescribed.
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) provides specific criteria for diagnosing sedative, hypnotic, or anxiolytic use disorder. This diagnosis is made when an individual exhibits at least two of the following eleven criteria within a 12-month period:
The severity of sedative, hypnotic, or anxiolytic use disorder is determined by the number of criteria met:
Understanding these diagnostic criteria helps clinicians assess the severity of the disorder and develop appropriate treatment plans.
These disorders often develop through a progression that can begin with legitimate medical use:
Initial Prescription: A healthcare provider prescribes a benzodiazepine for anxiety or a sleep medication for insomnia, intending short-term use.
Tolerance Development: With regular use (sometimes in as little as 2-4 weeks), the body adapts to the medication, and the same dose becomes less effective.
Dose Escalation: To achieve the same therapeutic effect, the individual begins taking higher doses or using the medication more frequently than prescribed.
Physical Dependence: The brain and body adapt to the constant presence of the medication. Stopping or reducing the dose causes withdrawal symptoms.
Psychological Dependence: The person begins to rely on the medication not just for symptom relief but to function emotionally or cope with daily stressors.
Compulsive Use: Despite negative consequences (tolerance, dependence, impaired functioning), the person continues using and may engage in problematic behaviors such as doctor shopping or obtaining medications illicitly.
Other pathways to sedative, hypnotic, or anxiolytic use disorder include:
During Intoxication:
Signs of Chronic Use:
Withdrawal from sedatives, hypnotics, or anxiolytics can be medically dangerous and, in severe cases, life-threatening. Symptoms can include:
Mild to Moderate Withdrawal:
Severe Withdrawal (Medical Emergency):
Critical Note: Unlike withdrawal from opioids (which is intensely uncomfortable but rarely dangerous), withdrawal from sedatives, hypnotics, and anxiolytics can be fatal. Medical supervision during detoxification is essential for safety.
The timeline and severity of withdrawal depend on several factors:
Short-acting benzodiazepines (Xanax, Ativan) typically produce withdrawal symptoms within 6-12 hours, peaking at 24-72 hours.
Long-acting benzodiazepines (Valium, Klonopin) may not produce withdrawal symptoms for several days, with symptoms peaking at 5-7 days or later.
Chronic use and misuse of sedatives, hypnotics, and anxiolytics carry significant health risks:
Long-term use, particularly of benzodiazepines, is associated with:
Some cognitive effects may persist even after discontinuation, though many improve over time with abstinence.
Sedatives, hypnotics, and anxiolytics can cause fatal overdose, especially when:
The CDC has identified benzodiazepines as a major contributor to the overdose crisis, particularly in combination with opioids.
These medications impair coordination, balance, judgment, and reaction time, increasing the risk of:
Older adults are particularly vulnerable to adverse effects from sedatives, hypnotics, and anxiolytics:
The American Geriatrics Society’s Beers Criteria recommends avoiding benzodiazepines in older adults due to these risks.
Use during pregnancy can cause:
Medically supervised care is essential for pregnant individuals with sedative, hypnotic, or anxiolytic use disorder.
Many individuals with sedative, hypnotic, or anxiolytic use disorder also use other substances, particularly:
Polysubstance use significantly increases health risks and complicates treatment.
Sedative, hypnotic, or anxiolytic use disorders frequently co-occur with:
Integrated treatment addressing both the substance use disorder and co-occurring mental health conditions simultaneously produces the best outcomes.
Treatment for these disorders requires specialized medical care due to the serious risks associated with withdrawal. A comprehensive approach includes:
Unlike opioid withdrawal, withdrawal from sedatives, hypnotics, and anxiolytics can be life-threatening and requires medical supervision.
Gradual Tapering:
The safest approach involves slowly reducing the medication dose over weeks or months under medical supervision. This allows the brain and body to gradually readjust, minimizing withdrawal symptoms and eliminating seizure risk.
Stabilization and Crossover (for short-acting medications):
Individuals using short-acting benzodiazepines like Xanax or Ativan may be transitioned to a longer-acting benzodiazepine like Valium (diazepam), which is then gradually tapered. This provides more stable blood levels and smoother withdrawal.
Symptom Management:
During medically supervised detoxification, healthcare providers may use medications to manage specific withdrawal symptoms such as:
At CommonHealth Recovery, we work closely with detoxification facilities to ensure clients complete safe, medically supervised withdrawal before beginning our outpatient programs.
Once stabilized, ongoing treatment includes:
Cognitive Behavioral Therapy (CBT):
CBT helps individuals:
CBT has strong evidence for treating both substance use disorders and anxiety disorders.
Motivational Interviewing:
This approach helps strengthen personal motivation and commitment to change, addressing ambivalence about stopping medication use.
Trauma-Informed Care:
For individuals with histories of trauma or PTSD, trauma-focused therapy addresses underlying traumatic experiences that may have contributed to self-medication with sedatives or anxiolytics.
Relapse Prevention:
Learning to identify high-risk situations, manage cravings, develop coping strategies, and create relapse prevention plans.
A critical component of recovery is addressing the conditions for which sedatives, hypnotics, or anxiolytics were originally prescribed:
For Anxiety Disorders:
For Insomnia:
For Depression:
Our treatment approach includes:
Intensive Outpatient Program (IOP):
Standard Outpatient Treatment:
Integrated Mental Health Care:
We provide comprehensive treatment for co-occurring anxiety disorders, depression, PTSD, and other conditions, addressing both the substance use disorder and underlying mental health concerns simultaneously.
Case Management:
Practical support with:
Family Involvement:
When appropriate, we involve family members in treatment through:
Part of successful recovery involves learning non-pharmacological approaches to manage anxiety and sleep problems:
For Anxiety:
For Insomnia:
These evidence-based approaches are often more effective long-term than medications, without risks of dependence or side effects.
Recovery from sedative, hypnotic, or anxiolytic use disorder is a gradual process that requires:
Brain Recovery:
Cognitive function often improves after discontinuation, though recovery may take months. Some individuals experience protracted withdrawal symptoms (anxiety, sleep problems, cognitive difficulties) lasting weeks to months, which gradually improve with time and support.
Relapse Prevention:
Strategies include:
With appropriate treatment and support, individuals can successfully recover from sedative, hypnotic, or anxiolytic use disorders and achieve lasting wellness.
If you or someone you love is struggling with dependence on benzodiazepines, sleep medications, or other sedatives, CommonHealth Recovery is here to help.
Located in Frankfort, Kentucky, we serve residents throughout Central Kentucky, including Lexington, Louisville, Georgetown, Versailles, and surrounding communities.
Call (502) 661-1444 to speak with our admissions team about your situation and treatment options. We provide confidential, compassionate care and will work with you to develop a safe treatment plan.
Important: If you’re currently using benzodiazepines or other sedatives regularly, do not stop abruptly without medical supervision. Sudden discontinuation can be dangerous. Our team can help you safely reduce and discontinue these medications under appropriate medical care.
Sedative, hypnotic, or anxiolytic use disorder is a substance use disorder involving problematic use of central nervous system depressants including benzodiazepines, sleep medications, and barbiturates. It’s diagnosed when an individual exhibits at least two of eleven specific criteria within a 12-month period, indicating loss of control over use, continued use despite harm, and pharmacological indicators like tolerance and withdrawal.
Benzodiazepine withdrawal varies based on the specific medication and duration of use. Short-acting benzodiazepines (Xanax, Ativan) typically produce acute withdrawal lasting 5-7 days, while long-acting benzodiazepines (Valium, Klonopin) may have acute withdrawal lasting 10-14 days or longer. Some individuals experience protracted withdrawal symptoms (anxiety, insomnia, cognitive difficulties) lasting weeks to months, which gradually improve with time.
Yes, benzodiazepine withdrawal can be life-threatening. Seizures can occur during withdrawal, and in severe cases, delirium and autonomic instability can develop. This is why medical supervision during detoxification is essential. Never stop benzodiazepines or other sedatives abruptly without medical guidance.
While both are addictive, they work through different mechanisms. Opioids bind to opioid receptors and primarily affect pain and reward pathways. Benzodiazepines enhance GABA activity and primarily affect anxiety, sedation, and seizure thresholds. Importantly, opioid withdrawal is uncomfortable but rarely life-threatening, while benzodiazepine withdrawal can be medically dangerous and even fatal.
The safest approach is a gradual taper under medical supervision, reducing the dose slowly over weeks or months. This allows the brain to readjust gradually, minimizing withdrawal symptoms and eliminating seizure risk. Sometimes transitioning to a longer-acting benzodiazepine like Valium first makes tapering smoother.
Yes. For anxiety, SSRIs, SNRIs, buspirone, and psychotherapy (especially CBT) are effective non-addictive options. For insomnia, cognitive-behavioral therapy for insomnia (CBT-I) is considered the first-line treatment and is more effective long-term than medications without risks of dependence.
Clinical guidelines generally recommend benzodiazepines for short-term use only (2-4 weeks) due to risks of tolerance and dependence. However, many individuals end up taking them long-term. If you’ve been taking benzodiazepines long-term, work with a healthcare provider to develop a safe tapering plan rather than continuing indefinitely.
Benzodiazepine use during pregnancy carries risks including fetal sedation, neonatal withdrawal syndrome, and potential birth defects. If you’re pregnant or planning pregnancy and taking benzodiazepines, work closely with your healthcare providers to develop the safest plan, which may include a medically supervised taper or transitioning to safer alternatives.
If you’re concerned about dependence on benzodiazepines, sleep medications, or other sedatives, help is available. Don’t attempt to stop these medications on your own.
Call CommonHealth Recovery at (502) 661-1444 for a confidential consultation about safe, supervised treatment options.
CommonHealth Recovery
Evidence-based treatment for substance use and mental health disorders in Frankfort, Kentucky.
